BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

651 related articles for article (PubMed ID: 35733235)

  • 1. COVID-19 coagulopathy - what should we treat?
    Chowdary P
    Exp Physiol; 2022 Jul; 107(7):749-758. PubMed ID: 35733235
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathomechanisms Underlying Hypoxemia in Two COVID-19-Associated Acute Respiratory Distress Syndrome Phenotypes: Insights From Thrombosis and Hemostasis.
    Gando S; Wada T
    Shock; 2022 Jan; 57(1):1-6. PubMed ID: 34172612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impaired coagulation, liver dysfunction and COVID-19: Discovering an intriguing relationship.
    D'Ardes D; Boccatonda A; Cocco G; Fabiani S; Rossi I; Bucci M; Guagnano MT; Schiavone C; Cipollone F
    World J Gastroenterol; 2022 Mar; 28(11):1102-1112. PubMed ID: 35431501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Venous thrombosis epidemiology, pathophysiology, and anticoagulant therapies and trials in severe acute respiratory syndrome coronavirus 2 infection.
    Obi AT; Barnes GD; Napolitano LM; Henke PK; Wakefield TW
    J Vasc Surg Venous Lymphat Disord; 2021 Jan; 9(1):23-35. PubMed ID: 32916371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Viral Coagulopathy in Patients With COVID-19: Treatment and Care.
    Kipshidze N; Dangas G; White CJ; Kipshidze N; Siddiqui F; Lattimer CR; Carter CA; Fareed J
    Clin Appl Thromb Hemost; 2020; 26():1076029620936776. PubMed ID: 32687449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. COVID-19: Coagulopathy, Risk of Thrombosis, and the Rationale for Anticoagulation.
    Miesbach W; Makris M
    Clin Appl Thromb Hemost; 2020; 26():1076029620938149. PubMed ID: 32677459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The coagulopathy, endotheliopathy, and vasculitis of COVID-19.
    Iba T; Connors JM; Levy JH
    Inflamm Res; 2020 Dec; 69(12):1181-1189. PubMed ID: 32918567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The CHARTER-Ireland trial: can nebulised heparin reduce acute lung injury in patients with SARS-CoV-2 requiring advanced respiratory support in Ireland: a study protocol and statistical analysis plan for a randomised control trial.
    Sheehan JR; Calpin P; Kernan M; Kelly C; Casey S; Murphy D; Alvarez-Iglesias A; Giacomini C; Cody C; Curley G; McGeary S; Hanley C; McNicholas B; van Haren F; Laffey JG; Cosgrave D
    Trials; 2022 Sep; 23(1):774. PubMed ID: 36104785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fibrinolytic abnormalities in acute respiratory distress syndrome (ARDS) and versatility of thrombolytic drugs to treat COVID-19.
    Whyte CS; Morrow GB; Mitchell JL; Chowdary P; Mutch NJ
    J Thromb Haemost; 2020 Jul; 18(7):1548-1555. PubMed ID: 32329246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anticoagulation for COVID-19 Patients: A Bird's-Eye View.
    Kreidieh F; Temraz S
    Clin Appl Thromb Hemost; 2021; 27():10760296211039288. PubMed ID: 34595937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathogenesis-directed therapy of 2019 novel coronavirus disease.
    Stratton CW; Tang YW; Lu H
    J Med Virol; 2021 Mar; 93(3):1320-1342. PubMed ID: 33073355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Coagulation, fibrinolysis, and fibrin deposition in acute lung injury.
    Idell S
    Crit Care Med; 2003 Apr; 31(4 Suppl):S213-20. PubMed ID: 12682443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nebulised heparin as a treatment for COVID-19: scientific rationale and a call for randomised evidence.
    van Haren FMP; Page C; Laffey JG; Artigas A; Camprubi-Rimblas M; Nunes Q; Smith R; Shute J; Carroll M; Tree J; Carroll M; Singh D; Wilkinson T; Dixon B
    Crit Care; 2020 Jul; 24(1):454. PubMed ID: 32698853
    [TBL] [Abstract][Full Text] [Related]  

  • 14. COVID-19 Infection: Viral Macro- and Micro-Vascular Coagulopathy and Thromboembolism/Prophylactic and Therapeutic Management.
    Manolis AS; Manolis TA; Manolis AA; Papatheou D; Melita H
    J Cardiovasc Pharmacol Ther; 2021 Jan; 26(1):12-24. PubMed ID: 32924567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. COVID-19: Thrombosis, thromboinflammation, and anticoagulation considerations.
    Levy JH; Iba T; Olson LB; Corey KM; Ghadimi K; Connors JM
    Int J Lab Hematol; 2021 Jul; 43 Suppl 1(Suppl 1):29-35. PubMed ID: 34288441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thromboinflammation in COVID-19 acute lung injury.
    Mitchell WB
    Paediatr Respir Rev; 2020 Sep; 35():20-24. PubMed ID: 32653469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adult respiratory distress syndrome: do selective anticoagulants help?
    Idell S
    Am J Respir Med; 2002; 1(6):383-91. PubMed ID: 14720025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thrombosis in Coronavirus disease 2019 (COVID-19) through the prism of Virchow's triad.
    Ahmed S; Zimba O; Gasparyan AY
    Clin Rheumatol; 2020 Sep; 39(9):2529-2543. PubMed ID: 32654082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SARS-CoV-2 Spike Proteins and Cell-Cell Communication Inhibits TFPI and Induces Thrombogenic Factors in Human Lung Microvascular Endothelial Cells and Neutrophils: Implications for COVID-19 Coagulopathy Pathogenesis.
    Bhargavan B; Kanmogne GD
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced platelet inhibition treatment improves hypoxemia in patients with severe Covid-19 and hypercoagulability. A case control, proof of concept study.
    Viecca M; Radovanovic D; Forleo GB; Santus P
    Pharmacol Res; 2020 Aug; 158():104950. PubMed ID: 32450344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.